Intersect ENT (XENT) and The Competition Financial Analysis

Intersect ENT (NASDAQ: XENT) is one of 84 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its competitors? We will compare Intersect ENT to similar companies based on the strength of its analyst recommendations, earnings, profitability, dividends, institutional ownership, valuation and risk.

Analyst Recommendations

This is a summary of recent ratings and target prices for Intersect ENT and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intersect ENT 0 2 8 0 2.80
Intersect ENT Competitors 170 1120 2457 89 2.64

Intersect ENT presently has a consensus price target of $27.11, indicating a potential downside of 5.54%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 9.45%. Given Intersect ENT’s competitors higher possible upside, analysts plainly believe Intersect ENT has less favorable growth aspects than its competitors.

Institutional and Insider Ownership

83.1% of Intersect ENT shares are owned by institutional investors. Comparatively, 63.1% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 13.7% of Intersect ENT shares are owned by company insiders. Comparatively, 12.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Intersect ENT and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Intersect ENT $87.16 million -$19.71 million -41.00
Intersect ENT Competitors $827.23 million $159.49 million 36.42

Intersect ENT’s competitors have higher revenue and earnings than Intersect ENT. Intersect ENT is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Intersect ENT has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Intersect ENT’s competitors have a beta of 1.06, indicating that their average share price is 6% more volatile than the S&P 500.


This table compares Intersect ENT and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intersect ENT -22.94% -17.60% -15.64%
Intersect ENT Competitors -127.09% -36.26% -10.19%

Intersect ENT Company Profile

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company’s commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.

Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with's FREE daily email newsletter.

Leave a Reply